Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Tocilizumab (ausschließlich Darreichungsform PEN und FER), ATC L04AC07 für die Zeit 01.08.2026 - 31.07.2028

Section 130a, paragraph 8 of the German Social Code (SGB V) allows health insurance funds and pharmaceutical companies to conclude framework rebate contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the German Act Against Restraints of Competition (GWB) for the pharmaceuticals to be specified by the bidder in Annex 2 to the contract. For the pharmaceuticals to be specified by the bidder in Annex 2 to the contract, the DAK-Gesundheit intends to conclude rebate contracts with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical rebate contracts. The first rebate contract under the approval model for the aforementioned active substance Tocilizumab (exclusively in the dosage forms PEN and FER), ATC L04AC07, will come into force on 01.08.2026 and will end on 31.07.2028. It will automatically end with the entry into force of the exclusive contract, regardless.